Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.
Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.
Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.
Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, December 9 at 8:30 a.m. ET. The event will present topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in children with respiratory syncytial virus (RSV). The study focused on both hospitalized and non-hospitalized children aged 28 days to 36 months.
The live webcast will be accessible through the company's website under the 'Events & Presentations' section in the investors area. Participants joining by phone are advised to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on Enanta's website for approximately 30 days after the event.
Enanta Pharmaceuticals reported financial results for Q4 and fiscal year 2024. Total revenue was $14.6M for Q4 and $67.6M for FY2024, down from $18.9M and $79.2M respectively in 2023, due to declining MAVYRET®/MAVIRET® sales. Net loss was $28.8M ($1.36 per share) in Q4 and $116.0M ($5.48 per share) for FY2024.
The company announced positive Phase 2a results for EDP-323 in RSV treatment and expanded its immunology portfolio with a new STAT6 inhibition program and EPS-1421 development candidate. Cash position stands at $248.2M, expected to fund operations into fiscal 2027.
Enanta Pharmaceuticals announced positive topline results from a Phase 2a human challenge study of EDP-323, a novel L-protein inhibitor for RSV treatment. The study demonstrated:
- 85-87% reduction in viral load AUC by qRT-PCR (p<0.0001)
- 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001)
- 66-78% reduction of total clinical symptoms score AUC (p<0.0001)
EDP-323 showed a favorable safety profile and pharmacokinetics supporting once-daily dosing. The drug achieved rapid and sustained antiviral effects, with results among the strongest reported in an RSV challenge study. Enanta aims to develop EDP-323 as a safe, effective oral treatment for RSV, addressing a substantial unmet medical need.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company, has announced its participation in three upcoming investor conferences in September 2024. The company's management will be involved in fireside chats at the following events:
- Baird 2024 Global Healthcare Conference on September 10 at 2:35 p.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 10:00 a.m. ET
- 2024 Cantor Global Healthcare Conference on September 17 at 10:55 a.m. ET
Live webcasts of these events will be available on the 'Events and Presentations' section of Enanta's website. Replays will be archived for at least 30 days after the presentations.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for its fiscal third quarter ended June 30, 2024. Total revenue was $18.0 million, consisting of royalty revenue from AbbVie's HCV regimen MAVYRET/MAVIRET. The company reported a net loss of $22.7 million, or $1.07 per diluted share. Enanta's cash and marketable securities totaled $272.6 million as of June 30, 2024.
Key highlights include:
- Completion of enrollment for RSVPEDs, a Phase 2 study of zelicapavir in pediatric RSV patients
- Completion of EDP-323 Phase 2a Challenge Study in RSV
- Advancement of KIT inhibitors for chronic spontaneous urticaria
- Expected cash runway through Q3 2027
Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs for virology and immunology, has announced its participation at the Jefferies Global Healthcare Conference. The event will feature a fireside chat with President and CEO Jay R. Luly, Ph.D., and Chief Product Strategy Officer Tara L. Kieffer, Ph.D. The session is set for June 5, 2024, at 7:30 a.m. ET in New York, NY. A live webcast of the discussion will be available on Enanta's website, with a replay accessible for at least 30 days post-event.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in the JMP Securities Life Sciences Conference with their CEO and Chief Product Strategy Officer, discussing small molecule drugs for virology and immunology. The event will be live webcasted and available for replay on Enanta's website.
Enanta Pharmaceuticals, a clinical-stage biotechnology company, reported financial results for Q2 of fiscal year 2024. The company anticipates reporting topline data from RSV studies, phase 2 study of Zelicapavir, and CSU development candidate selection in 2024. Enanta's revenue was $17.1 million, with research and development expenses of $35.6 million. The company's operations are supported by $300.3 million in cash and marketable securities. Enanta is focused on advancing antiviral treatments for RSV and immunology indications.
Enanta Pharmaceuticals, Inc. announced inducement grants to its new Chief Legal Officer, Matthew P. Kowalsky, involving stock options, performance share units, and relative total stockholder return units under the company's 2024 Inducement Stock Incentive Plan. These awards are aimed at incentivizing Mr. Kowalsky's performance and retention within the company.
Enanta Pharmaceuticals, Inc. announced the appointment of Matthew P. Kowalsky as Chief Legal Officer. With over 20 years of legal experience in the life sciences industry, he will lead all legal and compliance activities for Enanta, providing strategic guidance and corporate governance oversight. Kowalsky's background includes roles at Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals, and Lantheus Medical Imaging, among others. His expertise in corporate governance, public company reporting, intellectual property, financing, and business development makes him a valuable addition to Enanta's leadership team.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
